国家专利中药复方改善肿瘤患者免疫功能的用药规律分析.

Objective To analyze the medication rule and composition characteristics of national patent Chinese medicine compound for improving the immune function of tumor patients. Methods We obtained the patent data of Chinese medicine compound for improving the immune function of tumor patients from 1993 to 2022 by searching the patent database of the China National Intellectual Property Administration. Microsoft Excel 2016 was used to establish a prescription database and standardize the processing of data. IBM SPSS Modeler 18.0, Microsoft Excel 2016 and IBM SPSS Statistics 26.0 were used for Apriori association rule analysis, drug frequency statistics and system clustering analysis. Results A total of 107 patents for Chinese medicine compound for improving the immune function of tumor patients was included, involving 339 Chinese medicines, with a total medication frequency of 994 times. Twenty-two high-frequency (frequency ≥ 9 times) Chinese herbal medicines were analyzed. The most frequently used Chinese herbal medicine is Astragali Radix. Systematic clustering analysis on high-frequency Chinese medicine was conducted, and the results are divided into six categories. After analyzing the association rules of Chinese medicine with a frequency of ≥ 2, we obtained high-frequency drug pairs such as "Astragali Radix- Ginseng Radix et Rhizoma" and "Astragali Radix- Angelicae Sinensis Radix". The combination of triplet medicinals with high confidence was "Atractylodis Macrocephalae Rhizoma- Astragali Radix-Angelicae Sinensis Radix", "Glycyrrhizae Radix et Rhizoma- Astragali Radix-Ginseng Radix et Rhizoma" and "Poria- Lycii Fructus- Angelicae Sinensis Radix", et al. The four properties are mainly cold, warm and calm, while the five flavors are mainly bitter, sweet and pungent. They mostly belong to the liver, spleen and kidney meridians. The most frequently used Chinese medicine are tonifying deficiency drugs and promoting blood circulation and resolving stasis drugs. Conclusion National patent Chinese medicine compound mainly improves the immune function of tumor patients by tonifying deficiency drugs and invigorating blood and resolving blood stasis drugs, which is in line with the pathogenesis characteristics of deficiency and blood stasis in traditional Chinese medicine. The treatment has the characteristic of treating both manifestation and root cause, and is in good agreement with the theoretical basis of traditional Chinese medicine in improving the immune function of tumor patients. [ABSTRACT FROM AUTHOR]